Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

Frontiers in transplantation Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI:10.3389/frtra.2024.1405070
Moritz Anft, Panagiota Zgoura, Sarah Skrzypczyk, Michael Dürr, Richard Viebahn, Timm H Westhoff, Ulrik Stervbo, Nina Babel
{"title":"Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.","authors":"Moritz Anft, Panagiota Zgoura, Sarah Skrzypczyk, Michael Dürr, Richard Viebahn, Timm H Westhoff, Ulrik Stervbo, Nina Babel","doi":"10.3389/frtra.2024.1405070","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C<sub>max</sub> with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-release tacrolimus (IR-Tac). Once-daily LCPT in <i>de novo</i> kidney transplantation has a comparable efficacy and safety profile to that of IR-Tac with advantages in bioavailability and absorption. The present investigation intends to analyze the effects of conversion from IR-Tac to LCPT on phenotype and function of T-cells and B-cells.</p><p><strong>Methods: </strong>16 kidney transplant patients treated by triple standard immunosuppression with a stable graft function undergoing a switch from IR-Tac to LCPT were included in this observational prospective study. We measured the main immune cell types and performed an in-depth characterization of B cell, dendritic cells and T cells including regulatory T cells of the patients before, 4 and 8 weeks after IR-Tac to LCPT conversion using multi-parameter fl ow cytometry. Additionally, we analyzed T cells by assessing third-party antigens (Tetanus Diphtheria, TD)-reactive T cells, which could be analyzed by restimulation with tetanus vaccine.</p><p><strong>Results: </strong>Overall, we found no significant alterations following LCPT conversion for the most immune cell populations with a few cell populations showing transient quantitative increase. Thus, 4 weeks after conversion, more regulatory T cells could be measured in the patients with a significant shift from memory to naïve Tregs. Furthermore, we found a transient B cell expansion 4 weeks after conversion from IR-Tac to LCPT. There were no changes in the percentage of other basic immune cell types and the antigen-reactive T cells were also not altered after changing the medication to LCP-tacrolimus.</p><p><strong>Conclusion: </strong>Here, we demonstrate first insights into the immune system changes occurred under IR-Tac to LCPT conversion therapy in kidney transplant patients. While phenotypic and functional characteristics of the most immune cell populations did not change, we could observe an a transient expansion of regulatory T cells in peripheral blood following IR-Tac to LCTP conversion, which might additionally contribute to the overall immunosuppressive effect.</p>","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":"3 ","pages":"1405070"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461451/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2024.1405070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced Cmax with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-release tacrolimus (IR-Tac). Once-daily LCPT in de novo kidney transplantation has a comparable efficacy and safety profile to that of IR-Tac with advantages in bioavailability and absorption. The present investigation intends to analyze the effects of conversion from IR-Tac to LCPT on phenotype and function of T-cells and B-cells.

Methods: 16 kidney transplant patients treated by triple standard immunosuppression with a stable graft function undergoing a switch from IR-Tac to LCPT were included in this observational prospective study. We measured the main immune cell types and performed an in-depth characterization of B cell, dendritic cells and T cells including regulatory T cells of the patients before, 4 and 8 weeks after IR-Tac to LCPT conversion using multi-parameter fl ow cytometry. Additionally, we analyzed T cells by assessing third-party antigens (Tetanus Diphtheria, TD)-reactive T cells, which could be analyzed by restimulation with tetanus vaccine.

Results: Overall, we found no significant alterations following LCPT conversion for the most immune cell populations with a few cell populations showing transient quantitative increase. Thus, 4 weeks after conversion, more regulatory T cells could be measured in the patients with a significant shift from memory to naïve Tregs. Furthermore, we found a transient B cell expansion 4 weeks after conversion from IR-Tac to LCPT. There were no changes in the percentage of other basic immune cell types and the antigen-reactive T cells were also not altered after changing the medication to LCP-tacrolimus.

Conclusion: Here, we demonstrate first insights into the immune system changes occurred under IR-Tac to LCPT conversion therapy in kidney transplant patients. While phenotypic and functional characteristics of the most immune cell populations did not change, we could observe an a transient expansion of regulatory T cells in peripheral blood following IR-Tac to LCTP conversion, which might additionally contribute to the overall immunosuppressive effect.

从每日两次的他克莫司改为每日一次的缓释融化他克莫司对细胞免疫反应的影响。
背景:LCP-Tacro[LCPT]是一种新型的他克莫司日服一次缓释制剂,与速释他克莫司(IR-Tac)相比,其Cmax降低,AUC暴露相当,需要减少30%的剂量。在新生肾移植中,每日一次的 LCPT 具有与 IR-Tac 相似的疗效和安全性,但在生物利用度和吸收方面更具优势。本研究旨在分析从 IR-Tac 转为 LCPT 对 T 细胞和 B 细胞表型和功能的影响。方法:本观察性前瞻性研究共纳入了 16 例接受三联标准免疫抑制治疗且移植物功能稳定的肾移植患者,他们都是从 IR-Tac 转为 LCPT。我们测量了主要的免疫细胞类型,并在 IR-Tac 转 LCPT 前、4 周和 8 周后使用多参数荧光细胞计数法深入分析了患者的 B 细胞、树突状细胞和 T 细胞(包括调节性 T 细胞)的特征。此外,我们还通过评估第三方抗原(破伤风-白喉,TD)反应性 T 细胞来分析 T 细胞:总体而言,我们发现大多数免疫细胞群在 LCPT 转换后没有明显变化,只有少数细胞群出现短暂的数量增加。因此,在转化 4 周后,可以在患者体内检测到更多的调节性 T 细胞,记忆 Tregs 明显向幼稚 Tregs 转移。此外,我们还发现,从 IR-Tac 转为 LCPT 4 周后,B 细胞出现了短暂的扩增。其他基础免疫细胞类型的比例没有变化,抗原反应性T细胞在改用LCP-他克莫司后也没有改变:结论:在此,我们首次展示了肾移植患者从 IR-Tac 转为 LCPT 治疗后免疫系统发生的变化。虽然大多数免疫细胞群的表型和功能特征没有发生变化,但我们可以观察到,IR-Tac 转换为 LCTP 后,外周血中的调节性 T 细胞出现了短暂的扩增,这可能会对整体免疫抑制效果起到额外的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信